Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch
To the Editor: Peanut allergy (PA) affects approximately 1% to 1.5% of children and adults living in westernized society1 and is considered a life-long allergy in the vast majority of subjects.2,3 Additionally, peanuts and tree nuts account for 90% of all cases of fatal and near-fatal anaphylaxis to...
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2016-04, Vol.137 (4), p.1258-1261.e10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1261.e10 |
|---|---|
| container_issue | 4 |
| container_start_page | 1258 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 137 |
| creator | Jones, Stacie M., MD Agbotounou, Wence K., PhD Fleischer, David M., MD Burks, A. Wesley, MD Pesek, Robert D., MD Harris, Michael W., MD Martin, Laurent, PharmD Thebault, Claude, MD Ruban, Charles, MS Benhamou, Pierre-Henri, MD |
| description | To the Editor: Peanut allergy (PA) affects approximately 1% to 1.5% of children and adults living in westernized society1 and is considered a life-long allergy in the vast majority of subjects.2,3 Additionally, peanuts and tree nuts account for 90% of all cases of fatal and near-fatal anaphylaxis to foods.4 Strict dietary avoidance and availability of injectable epinephrine are key management tools in the current food allergy guidelines,2 and the quest for effective allergen immunotherapy for PA is ongoing.5 Epicutaneous immunotherapy (EPIT) has shown promise in animal studies6-8 and in a single pilot study9 as a novel future treatment for food allergy. Preclinical studies indicate that allergen applied through EPIT to intact skin does not cross into the circulation but rather activates dendritic cells in the dermal layer of the skin to affect immune activation.5 The findings presented in this letter expand the data presented in abstract form10 to include a comprehensive analysis of the phase 1 study. |
| doi_str_mv | 10.1016/j.jaci.2016.01.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1779881908</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674916001299</els_id><sourcerecordid>1779881908</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-abe6e22c024af2699c63740f9fc23fd96efddb0d0d4fc2bf0aeecc0cb67bcf763</originalsourceid><addsrcrecordid>eNp9ks1u1TAQhS0EopfCC7BAltiwSRg7uU6MUKWq4k-qxKLA1nKcca_T_GE7SHkbnoUnw-ktIHXBymPrO0czPkPIcwY5AyZed3mnjct5qnNgOUD9gOwYyCoTNd8_JDsAyTJRlfKEPAmhg3QvavmYnHAhOZSi2BF_pS3GlU6W4uzMEvWI0xKoG4ZlnOIBvZ5XaidPU02jRx0HHOPGz6jHJVLd9-iv1zf0_NfP-aADUkZDXNqVLsGN17e6b06HGzfSWUdzeEoeWd0HfHZ3npKv7999ufiYXX7-8Oni_DIz-1LGTDcokHMDvNQ2NSyNKKoSrLSGF7aVAm3bNtBCW6aXxoJGNAZMI6rG2EoUp-TV0Xf20_cFQ1SDCwb7_jiiYlUl65pJqBP68h7aTYsfU3eJqqGCfbnfKH6kjJ9C8GjV7N2g_aoYqC0R1aktEbUlooApuLV-cWe9NAO2fyV_IkjA2yOA6S9-OPQqGIejwdZ5NFG1k_u__9k9uend6Izub3DF8G8OFbgCdbXtxLYSTAAwLmXxG7xCtDk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780705458</pqid></control><display><type>article</type><title>Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Jones, Stacie M., MD ; Agbotounou, Wence K., PhD ; Fleischer, David M., MD ; Burks, A. Wesley, MD ; Pesek, Robert D., MD ; Harris, Michael W., MD ; Martin, Laurent, PharmD ; Thebault, Claude, MD ; Ruban, Charles, MS ; Benhamou, Pierre-Henri, MD</creator><creatorcontrib>Jones, Stacie M., MD ; Agbotounou, Wence K., PhD ; Fleischer, David M., MD ; Burks, A. Wesley, MD ; Pesek, Robert D., MD ; Harris, Michael W., MD ; Martin, Laurent, PharmD ; Thebault, Claude, MD ; Ruban, Charles, MS ; Benhamou, Pierre-Henri, MD</creatorcontrib><description>To the Editor: Peanut allergy (PA) affects approximately 1% to 1.5% of children and adults living in westernized society1 and is considered a life-long allergy in the vast majority of subjects.2,3 Additionally, peanuts and tree nuts account for 90% of all cases of fatal and near-fatal anaphylaxis to foods.4 Strict dietary avoidance and availability of injectable epinephrine are key management tools in the current food allergy guidelines,2 and the quest for effective allergen immunotherapy for PA is ongoing.5 Epicutaneous immunotherapy (EPIT) has shown promise in animal studies6-8 and in a single pilot study9 as a novel future treatment for food allergy. Preclinical studies indicate that allergen applied through EPIT to intact skin does not cross into the circulation but rather activates dendritic cells in the dermal layer of the skin to affect immune activation.5 The findings presented in this letter expand the data presented in abstract form10 to include a comprehensive analysis of the phase 1 study.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2016.01.008</identifier><identifier>PMID: 26920463</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Cutaneous ; Adolescent ; Adult ; Adults ; Age ; Allergy and Immunology ; Child ; Compliance ; Desensitization, Immunologic - adverse effects ; Desensitization, Immunologic - instrumentation ; Desensitization, Immunologic - methods ; Diaries ; Dictionaries ; Double-Blind Method ; Edema ; Female ; Follow-Up Studies ; Food allergies ; Humans ; Immunotherapy ; Male ; Middle Aged ; Patient Compliance ; Peanut Hypersensitivity - therapy ; Treatment Outcome ; Young Adult</subject><ispartof>Journal of allergy and clinical immunology, 2016-04, Vol.137 (4), p.1258-1261.e10</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2016 American Academy of Allergy, Asthma & Immunology</rights><rights>Copyright Elsevier Limited Apr 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-abe6e22c024af2699c63740f9fc23fd96efddb0d0d4fc2bf0aeecc0cb67bcf763</citedby><cites>FETCH-LOGICAL-c549t-abe6e22c024af2699c63740f9fc23fd96efddb0d0d4fc2bf0aeecc0cb67bcf763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaci.2016.01.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26920463$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jones, Stacie M., MD</creatorcontrib><creatorcontrib>Agbotounou, Wence K., PhD</creatorcontrib><creatorcontrib>Fleischer, David M., MD</creatorcontrib><creatorcontrib>Burks, A. Wesley, MD</creatorcontrib><creatorcontrib>Pesek, Robert D., MD</creatorcontrib><creatorcontrib>Harris, Michael W., MD</creatorcontrib><creatorcontrib>Martin, Laurent, PharmD</creatorcontrib><creatorcontrib>Thebault, Claude, MD</creatorcontrib><creatorcontrib>Ruban, Charles, MS</creatorcontrib><creatorcontrib>Benhamou, Pierre-Henri, MD</creatorcontrib><title>Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>To the Editor: Peanut allergy (PA) affects approximately 1% to 1.5% of children and adults living in westernized society1 and is considered a life-long allergy in the vast majority of subjects.2,3 Additionally, peanuts and tree nuts account for 90% of all cases of fatal and near-fatal anaphylaxis to foods.4 Strict dietary avoidance and availability of injectable epinephrine are key management tools in the current food allergy guidelines,2 and the quest for effective allergen immunotherapy for PA is ongoing.5 Epicutaneous immunotherapy (EPIT) has shown promise in animal studies6-8 and in a single pilot study9 as a novel future treatment for food allergy. Preclinical studies indicate that allergen applied through EPIT to intact skin does not cross into the circulation but rather activates dendritic cells in the dermal layer of the skin to affect immune activation.5 The findings presented in this letter expand the data presented in abstract form10 to include a comprehensive analysis of the phase 1 study.</description><subject>Administration, Cutaneous</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Child</subject><subject>Compliance</subject><subject>Desensitization, Immunologic - adverse effects</subject><subject>Desensitization, Immunologic - instrumentation</subject><subject>Desensitization, Immunologic - methods</subject><subject>Diaries</subject><subject>Dictionaries</subject><subject>Double-Blind Method</subject><subject>Edema</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Food allergies</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Compliance</subject><subject>Peanut Hypersensitivity - therapy</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks1u1TAQhS0EopfCC7BAltiwSRg7uU6MUKWq4k-qxKLA1nKcca_T_GE7SHkbnoUnw-ktIHXBymPrO0czPkPIcwY5AyZed3mnjct5qnNgOUD9gOwYyCoTNd8_JDsAyTJRlfKEPAmhg3QvavmYnHAhOZSi2BF_pS3GlU6W4uzMEvWI0xKoG4ZlnOIBvZ5XaidPU02jRx0HHOPGz6jHJVLd9-iv1zf0_NfP-aADUkZDXNqVLsGN17e6b06HGzfSWUdzeEoeWd0HfHZ3npKv7999ufiYXX7-8Oni_DIz-1LGTDcokHMDvNQ2NSyNKKoSrLSGF7aVAm3bNtBCW6aXxoJGNAZMI6rG2EoUp-TV0Xf20_cFQ1SDCwb7_jiiYlUl65pJqBP68h7aTYsfU3eJqqGCfbnfKH6kjJ9C8GjV7N2g_aoYqC0R1aktEbUlooApuLV-cWe9NAO2fyV_IkjA2yOA6S9-OPQqGIejwdZ5NFG1k_u__9k9uend6Izub3DF8G8OFbgCdbXtxLYSTAAwLmXxG7xCtDk</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Jones, Stacie M., MD</creator><creator>Agbotounou, Wence K., PhD</creator><creator>Fleischer, David M., MD</creator><creator>Burks, A. Wesley, MD</creator><creator>Pesek, Robert D., MD</creator><creator>Harris, Michael W., MD</creator><creator>Martin, Laurent, PharmD</creator><creator>Thebault, Claude, MD</creator><creator>Ruban, Charles, MS</creator><creator>Benhamou, Pierre-Henri, MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20160401</creationdate><title>Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch</title><author>Jones, Stacie M., MD ; Agbotounou, Wence K., PhD ; Fleischer, David M., MD ; Burks, A. Wesley, MD ; Pesek, Robert D., MD ; Harris, Michael W., MD ; Martin, Laurent, PharmD ; Thebault, Claude, MD ; Ruban, Charles, MS ; Benhamou, Pierre-Henri, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-abe6e22c024af2699c63740f9fc23fd96efddb0d0d4fc2bf0aeecc0cb67bcf763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Administration, Cutaneous</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Child</topic><topic>Compliance</topic><topic>Desensitization, Immunologic - adverse effects</topic><topic>Desensitization, Immunologic - instrumentation</topic><topic>Desensitization, Immunologic - methods</topic><topic>Diaries</topic><topic>Dictionaries</topic><topic>Double-Blind Method</topic><topic>Edema</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Food allergies</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Compliance</topic><topic>Peanut Hypersensitivity - therapy</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jones, Stacie M., MD</creatorcontrib><creatorcontrib>Agbotounou, Wence K., PhD</creatorcontrib><creatorcontrib>Fleischer, David M., MD</creatorcontrib><creatorcontrib>Burks, A. Wesley, MD</creatorcontrib><creatorcontrib>Pesek, Robert D., MD</creatorcontrib><creatorcontrib>Harris, Michael W., MD</creatorcontrib><creatorcontrib>Martin, Laurent, PharmD</creatorcontrib><creatorcontrib>Thebault, Claude, MD</creatorcontrib><creatorcontrib>Ruban, Charles, MS</creatorcontrib><creatorcontrib>Benhamou, Pierre-Henri, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jones, Stacie M., MD</au><au>Agbotounou, Wence K., PhD</au><au>Fleischer, David M., MD</au><au>Burks, A. Wesley, MD</au><au>Pesek, Robert D., MD</au><au>Harris, Michael W., MD</au><au>Martin, Laurent, PharmD</au><au>Thebault, Claude, MD</au><au>Ruban, Charles, MS</au><au>Benhamou, Pierre-Henri, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>137</volume><issue>4</issue><spage>1258</spage><epage>1261.e10</epage><pages>1258-1261.e10</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>To the Editor: Peanut allergy (PA) affects approximately 1% to 1.5% of children and adults living in westernized society1 and is considered a life-long allergy in the vast majority of subjects.2,3 Additionally, peanuts and tree nuts account for 90% of all cases of fatal and near-fatal anaphylaxis to foods.4 Strict dietary avoidance and availability of injectable epinephrine are key management tools in the current food allergy guidelines,2 and the quest for effective allergen immunotherapy for PA is ongoing.5 Epicutaneous immunotherapy (EPIT) has shown promise in animal studies6-8 and in a single pilot study9 as a novel future treatment for food allergy. Preclinical studies indicate that allergen applied through EPIT to intact skin does not cross into the circulation but rather activates dendritic cells in the dermal layer of the skin to affect immune activation.5 The findings presented in this letter expand the data presented in abstract form10 to include a comprehensive analysis of the phase 1 study.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26920463</pmid><doi>10.1016/j.jaci.2016.01.008</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2016-04, Vol.137 (4), p.1258-1261.e10 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1779881908 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); EZB-FREE-00999 freely available EZB journals |
| subjects | Administration, Cutaneous Adolescent Adult Adults Age Allergy and Immunology Child Compliance Desensitization, Immunologic - adverse effects Desensitization, Immunologic - instrumentation Desensitization, Immunologic - methods Diaries Dictionaries Double-Blind Method Edema Female Follow-Up Studies Food allergies Humans Immunotherapy Male Middle Aged Patient Compliance Peanut Hypersensitivity - therapy Treatment Outcome Young Adult |
| title | Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T07%3A06%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20epicutaneous%20immunotherapy%20for%20the%20treatment%20of%20peanut%20allergy:%20A%C2%A0phase%201%20study%20using%20the%20Viaskin%20patch&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Jones,%20Stacie%20M.,%20MD&rft.date=2016-04-01&rft.volume=137&rft.issue=4&rft.spage=1258&rft.epage=1261.e10&rft.pages=1258-1261.e10&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2016.01.008&rft_dat=%3Cproquest_cross%3E1779881908%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780705458&rft_id=info:pmid/26920463&rft_els_id=S0091674916001299&rfr_iscdi=true |